Literature DB >> 6314418

Neuroendocrine reactivity to nicotine in smokers.

O F Pomerleau, J B Fertig, L E Seyler, J Jaffe.   

Abstract

The present study explored neuropeptide responses to nicotine from smoking. Habitual smokers smoked research cigarettes of known strength under controlled laboratory conditions while blood samples were withdrawn unobtrusively for subsequent biochemical analysis. To provide a metric that reflected total nicotine intake and total neurohormonal output, data were integrated over time. Subjects were relatively unresponsive in the low-nicotine (0.48 mg) condition. In the high-nicotine (2.87 mg) condition, there were significant positive correlations between integrated plasma nicotine and plasma arginine vasopressin (r = +0.985), its carrier protein neurophysin I (r = +0.944), and beta-endorphin-beta-lipotropin (r = +0.977), but not adrenocorticotropic hormone. Data from an experiment that used an extraction step to remove beta-lipotropin corroborated the functional relationship between plasma nicotine and beta-endorphin implied by the original findings. Taking into account recent research on the role of neuropeptides in the modulation of affective states and cognitive function as well as of other CNS activity, the present findings were interpreted as strengthening the hypothesis that nicotine-stimulated neuropeptide release provides positive reinforcement for smoking.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6314418     DOI: 10.1007/bf00439275

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

1.  Effects of cigarette smoking on learning and retention.

Authors:  K Andersson
Journal:  Psychopharmacologia       Date:  1975

2.  Isolation, assay, and secretion of individual human neurophysins.

Authors:  A G Robinson
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

Review 3.  Peptides in the brain: the new endocrinology of the neuron.

Authors:  R Guillemin
Journal:  Science       Date:  1978-10-27       Impact factor: 47.728

4.  EEG and task performance after ACTH4-10 in man.

Authors:  W G Sannita; P Irwin; M Fink
Journal:  Neuropsychobiology       Date:  1976       Impact factor: 2.328

5.  Acute hormonal response to cigarette smoking.

Authors:  W W Winternitz; D Quillen
Journal:  J Clin Pharmacol       Date:  1977-07       Impact factor: 3.126

6.  Influence of vasopressin on learning and memory.

Authors:  J J Legros; P Gilot; X Seron; J Claessens; A Adam; J M Moeglen; A Audibert; P Berchier
Journal:  Lancet       Date:  1978-01-07       Impact factor: 79.321

7.  A specific homologous radioimmunoassay for human beta-endorphin: direct measurement in biological fluids.

Authors:  M M Wilkes; R D Stewart; J F Bruni; M E Quigley; S S Yen; N Ling; M Chrétien
Journal:  J Clin Endocrinol Metab       Date:  1980-02       Impact factor: 5.958

8.  Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events.

Authors:  P E Cryer; M W Haymond; J V Santiago; S D Shah
Journal:  N Engl J Med       Date:  1976-09-09       Impact factor: 91.245

9.  Simultaneous determination of human plasma immunoreactive beta-lipotropin, gamma-lipotropin, and beta-endorphin using immuno-affinity chromatography.

Authors:  H Yamaguchi; A S Liotta; D T Krieger
Journal:  J Clin Endocrinol Metab       Date:  1980-11       Impact factor: 5.958

10.  beta-Endorphin and adrenocorticotropin are selected concomitantly by the pituitary gland.

Authors:  R Guillemin; T Vargo; J Rossier; S Minick; N Ling; C Rivier; W Vale; F Bloom
Journal:  Science       Date:  1977-09-30       Impact factor: 47.728

View more
  30 in total

1.  Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice.

Authors:  Graciela N Balerio; Ester Aso; Rafael Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

2.  Attenuated adrenocorticotropic responses to psychological stress are associated with early smoking relapse.

Authors:  Mustafa al'Absi; Dorothy Hatsukami; Gary L Davis
Journal:  Psychopharmacology (Berl)       Date:  2005-04-15       Impact factor: 4.530

Review 3.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

4.  Naloxone does not affect cigarette smoking.

Authors:  R Nemeth-Coslett; R R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Naloxone precipitates nicotine abstinence syndrome in the rat.

Authors:  D H Malin; J R Lake; V A Carter; J S Cunningham; O B Wilson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Sex differences in hormonal responses to stress and smoking relapse: a prospective examination.

Authors:  Mustafa al'Absi; Motohiro Nakajima; Sharon Allen; Andrine Lemieux; Dorothy Hatsukami
Journal:  Nicotine Tob Res       Date:  2015-04       Impact factor: 4.244

7.  Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.

Authors:  Elise M Weerts; Gary S Wand; Hiroto Kuwabara; Xiaoqiang Xu; J James Frost; Dean F Wong; Mary E McCaul
Journal:  Addict Biol       Date:  2012-12-18       Impact factor: 4.280

8.  Acute HPA axis response to naltrexone differs in female vs. male smokers.

Authors:  Daniel J O Roche; Emma Childs; Alyssa M Epstein; Andrea C King
Journal:  Psychoneuroendocrinology       Date:  2009-10-17       Impact factor: 4.905

9.  Effect of nicotine on mRNA levels encoding opioid peptides, vasopressin and alpha 3 nicotinic receptor subunit in the rat.

Authors:  V Höllt; G Horn
Journal:  Clin Investig       Date:  1992 Mar-Apr

10.  Haemodynamic reactions to acute psychological stress and smoking status in a large community sample.

Authors:  Anna C Phillips; Geoff Der; Kate Hunt; Douglas Carroll
Journal:  Int J Psychophysiol       Date:  2009-05-04       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.